NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

NCT03842163

CompletedN/A

Sponsor: Pfizer

Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Interventions: Diagnosis of TTR amyloidosis cardiomyopathy

Countries: Australia, Austria, France, Italy, Portugal, Romania, Slovakia, Slovenia

The main purpose of this study is to determine the prevalence of ATTR Cardiomyopathy among patients admitted due to Left Ventricular Hypertrophy (LVH) \>15mm of unknown etiology by using a 99mTc-tracer scintigraphy based protocol

Eligibility overview

Sex: ALL

Age: 50 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* Patient signed inform consent.
* Males and Females.
* Age ≥50 years.
* Left ventricular hypertrophy (LVH) defined as end-diastolic LV maximum wall thickness (MWT) ≥15mm in Echocardiogram.
* Plan to undergo or recently underwent radionuclide bone scintigraphy and/or SPECT with any of the following radio labelled tracers: 99mTc-DPD or 99mTc-PYP or 99mTc-HMDP.

Exclusion criteria:

* Etiological diagnosis explaining the LVH (p.e. Sarcomeric HCM, Myeloma, Fabry disease, Sarcoidosis, Any type of amyloidosis (AA, AL, TTR)
* Severe aortic stenosis defined as aortic valve area (AVA) \< 1.0 cm2

Locations (18)

Chermside, Australia
Melbourne, Australia
Innsbruck, Austria
Caen, Cedex, France
Créteil, France
Nantes, France
Toulouse, France
Bologna, Italy
Florence, Italy
Coimbra, Portugal
Lisbon, Portugal
Bucharest, Romania
Bucharest, Romania
Košice, Slovakia
Ljubljana, Slovenia
Majadahonda, Madrid, Spain
A Coruña, Spain
London, United Kingdom